Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia

Infection and Immunity

Volumn 70, Issue 3, 2002, Pages 1069-1074

  Gigliotti, Francis ^a   Haidaris, Constantine G ^a   Wright, Terry W ^a   Harmsen, Allen G ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; PNEUMOCYSTIS CARINII PNEUMONIA ANTIBODY; PROTOZOON ANTIBODY; UNCLASSIFIED DRUG;

AIRBORNE INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; EPITOPE MAPPING; GENE SWITCHING; GENETIC VARIABILITY; IMMUNOGLOBULIN GENE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFECTION RISK; MOUSE; NONHUMAN; NOSE MUCOSA; PASSIVE IMMUNIZATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; SCID MOUSE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; IMMUNIZATION, PASSIVE; MICE; MICE, SCID; PNEUMONIA, PNEUMOCYSTIS;

EID: 0036178014     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.3.1069-1074.2002     Document Type: Article

References (19)

1. Antibody to Pneumocystis carinii protects rats and mice from developing pneumonia
2. Prevention of varicella by zoster immune globulin
3. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection
4. Antibody-mediated shift in the profile of glycoprotein A phenotypes observed in a mouse model of Pneumocystis carinii pneumonia
5. Antigenic characterization of Pneumocystis carinii
6. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models
7. Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli
8. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice
9. Natural mode of acquisition for de novo infection with Pneumocystis carinii
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
11. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii
12. Kinetics of Crytosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum
13. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
14. Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient scid mice
15. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes
16. Introduction of Pneumocystis carinii in a colony of SCID mice
17. Generation of biologically active anti-Cryptococcus neoformans IgG, IgE, and IgA isotype switch variant antibodies by acridine orange mutagenesis
18. Intranasal antibody prophylaxis for protection against viral disease
19. Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases